Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jan 31 2025

Full Issue

FDA Green Lights New, Nonaddictive Pain Pill Journavx — But It's Pricey

The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a new generation of painkillers. However, each pill costs $15.50.

The New York Times: F.D.A. Approves Drug to Treat Pain Without Opioid Effects

The Food and Drug Administration approved a new medication Thursday to treat pain from an injury or surgery. It is expensive, with a list price of $15.50 per pill. But unlike opioid pain medicines, it cannot become addictive. That is because the drug, suzetrigine, made by Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside the brain, blocking pain signals. It cannot get into the brain. (Kolata, 1/30)

CNN: Journavx: FDA Approves First New Type Of Pain Medication In 25 Years 

Suzetrigine is the first new painkiller approved in the US since Celebrex, a type of nonsteroidal anti-inflammatory drug called a Cox-2 inhibitor, which was approved in 1998. ... The medication was discovered after researchers learned about a family of fire walkers in Pakistan and discovered that they lacked a gene allowing pain signals to fire in their skin. Members of this family could walk over hot coals without flinching. “They knew that they were on something hot; they knew they could feel the coals. So it’s not impacting the nerves that do heat and touch and stuff like that. It is just these pain-conducting nerves,” said Stuart Arbuckle, chief operating officer of Vertex Pharmaceuticals. “They were, in every other way, normal.” Still, it took scientists 25 years to figure out how to exploit that pain-conducting mechanism to develop a medication. (Goodman, 1/30)

Also —

CBS News: New Stockton Lab Discovery Shows Promise In Fighting Fentanyl Crisis

Fentanyl overdose is the leading cause of death among Americans aged 18 to 45. It's a crisis that has impacted so many lives and families, but a new way of fighting fentanyl overdoses could be coming out of Stockton. In one of the labs inside the School of Pharmacy at the University of the Pacific is where a team discovered a new way to deliver naloxone, the chemical in Narcan that is used to combat overdoses, that they say will save even more lives. (Reynoso, 1/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF